Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivo